Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.94000.0000 (0.00%)
As of 10:40AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 483.71M
Enterprise value -33.14M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)9.90
Price/book (mrq)0.69
Enterprise value/revenue -0.68
Enterprise value/EBITDA 0.18

Trading information

Stock price history

Beta (5Y monthly) -0.95
52-week change 3-44.65%
S&P500 52-week change 316.55%
52-week high 33.9700
52-week low 31.3200
50-day moving average 31.7243
200-day moving average 32.3149

Share statistics

Avg vol (3-month) 3928.73k
Avg vol (10-day) 3992.08k
Shares outstanding 5251.87M
Implied shares outstanding 6251.87M
Float 8161.13M
% held by insiders 115.72%
% held by institutions 168.50%
Shares short (14 Nov 2023) 417.74M
Short ratio (14 Nov 2023) 417.4
Short % of float (14 Nov 2023) 410.07%
Short % of shares outstanding (14 Nov 2023) 47.05%
Shares short (prior month 12 Oct 2023) 420.72M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)-236,156.01%

Management effectiveness

Return on assets (ttm)-14.19%
Return on equity (ttm)-25.05%

Income statement

Revenue (ttm)48.5M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)733.30%
Gross profit (ttm)84.68M
EBITDA -180.97M
Net income avi to common (ttm)-190.1M
Diluted EPS (ttm)-0.7600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)575.43M
Total cash per share (mrq)2.29
Total debt (mrq)64.64M
Total debt/equity (mrq)9.27%
Current ratio (mrq)16.74
Book value per share (mrq)2.80

Cash flow statement

Operating cash flow (ttm)-163.33M
Levered free cash flow (ttm)-74.96M